Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.

Raimondi, L., De Luca, A., Costa, V., Amodio, N., Carina, V., Bellavia, D., et al. (2017). Circulating biomarkers in osteosarcoma: New translational tools for diagnosis and treatment. ONCOTARGET, 8(59), 100831-100851 [10.18632/oncotarget.19852].

Circulating biomarkers in osteosarcoma: New translational tools for diagnosis and treatment

Alessandro, Riccardo;
2017-01-01

Abstract

Osteosarcoma (OS) is a rare primary malignant bone tumour arising from primitive bone-forming mesenchymal cells, with high incidence in children and young adults, accounting for approximately 60% of all malignant bone tumours. Currently, long-term disease-free survival can be achieved by surgical treatment plus chemotherapy in approximately 60% of patients with localized extremity disease, and in 20-30% of patients with metastatic lung or bone disease. Diagnosis of primary lesions and recurrences is achieved by using radiological investigations and standard tissue biopsy, the latter being costly, painful and hardly repeatable for patients. Therefore, despite some recent advances, novel biomarkers for OS diagnosis, prediction of response to therapy, disease progression and chemoresistance, are urgently needed. Biological fluids such as blood represent a rich source of noninvasive cancer biomarkers, which allow to understand what is really happening inside the tumour, either at diagnosis or during disease progression. In this regard, liquid biopsy potentially represents an alternative and non-invasive method to detect tumour onset, progression and response to therapy. In this review, we will summarize the state of the art in this novel area, illustrating recent studies on OS. Although the data reported in literature seem preliminary, liquid biopsy represents a promising tool with the potential to be rapidly translated in the clinical practice.
2017
Raimondi, L., De Luca, A., Costa, V., Amodio, N., Carina, V., Bellavia, D., et al. (2017). Circulating biomarkers in osteosarcoma: New translational tools for diagnosis and treatment. ONCOTARGET, 8(59), 100831-100851 [10.18632/oncotarget.19852].
File in questo prodotto:
File Dimensione Formato  
Raimondi et al, 2017.pdf

accesso aperto

Dimensione 742.96 kB
Formato Adobe PDF
742.96 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/295629
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 44
social impact